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IntasomeFor Moloney murine leukemia virus (M-MuLV), sustained viral infections require expression from an integrated
provirus. For many applications, non-integrating retroviral vectors have been utilized to avoid the unwanted
effects of integration, however, the level of expression from unintegrated DNA is signiﬁcantly less than that
of integrated provirus. We ﬁnd that unintegrated DNA expression can be increased in the presence of HDAC
inhibitors, such as TSA, when applied in combination with integrase (IN) mutations. These mutants include
an active site mutation as well as catalytically active INs bearing mutations of K376 in the MuLV C-terminal
domain of IN. MuLV IN K376 is homologous to K266 in HIV-1 IN, a known substrate for acetylation. The
MuLV IN protein is acetylated by p300 in vitro, however, the effect of HDAC inhibitors on gene expression
from unintegrated DNA is not dependent on the acetylation state of MuLV IN K376.
© 2012 Elsevier Inc. All rights reserved.Introduction
Integration of double-stranded viral DNA into the host chromatin, a
hallmark of retroviral infection, is catalyzed by the virally encoded
integrase (IN) protein. IN consists of three distinct domains as
determined by limited proteolysis (Engelman and Craigie, 1992): the
N-terminal Zn2+ binding domain (NTD), catalytic core domain
(CCD), and the C-terminal domain (CTD). Various in vitro assays have
demonstrated that the IN protein alone is sufﬁcient to catalyze both
the 3′ processing and strand transfer reactions (Craigie et al., 1990;
Katz et al., 1990), however, in vivo, additional viral and cellular proteins
associate with the DNA and IN protein to form the functional pre-
integration complex (PIC) (Bowerman et al., 1989; Miller et al., 1997).
The PIC, a large nucleoprotein complex whose constituents vary
depending on the retrovirus, minimally contains the viral DNA and
the IN protein. Additional viral and cellular factors that have been
identiﬁed as components of the PIC include the viral capsid (CA)
and p12 proteins in MuLV (Bowerman et al., 1989; Prizan-Ravid et
al., 2010) but not HIV (Bukrinsky et al., 1993), and the cellular hostrine leukemia virus; PIC, pre-
ne deacetylase.
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rights reserved.factor LEDGF, present in HIV (Cherepanov et al., 2003) but not
MuLV (Llano et al., 2004). Common to PICs from both viruses is the
cellular protein barrier-to-autointegration factor (BAF), an 89 amino
acid cellular protein with non-speciﬁc DNA binding capabilities (Lee
and Craigie, 1998; Lin and Engelman, 2003). Further analysis of PICs iso-
lated from infected cells reveals that a protein structure is present at the
viral DNA ends (Wei et al., 1997), conferring protection from DNase
I cleavage up to ~20 bp from the termini (Wei et al., 1998). Evidence
for an extended footprint, approximately 200–250 bp from the viral
DNA ends, is uncovered when probed with Mu-mediated PCR (MM-
PCR) (Chen et al., 1999; Wei et al., 1998). This complex will be referred
to as the extended intasome, to distinguish it from the minimal inta-
some structure (Hare et al., 2010a) consisting of IN proteins and DNA
only. To date, an extended intasome protein structure that could pro-
vide protection of up to ~200–250 bp of DNA has not been formed in
vitro. While it is clear that the presence of IN is essential to formation
of the extended intasome, the exact nature of its composition remains
elusive (Chen et al., 1999; Wei et al., 1997, 1998).
The use of non-integrating retroviral vectors has been explored as
an alternative avenue for gene delivery in gene therapy applications
where expression is (generally) driven from internal promoters
rather than the viral LTR (Bayer et al., 2008; Nightingale et al., 2006;
Philippe et al., 2006; Rahim et al., 2009; Sloan and Wainberg, 2011;
Yu et al., 2008). Although in theory, integration of a therapeutic target
gene has many advantages over a non-integrating vector, the dangers
of integration are widely recognized. Integration and alteration of the
host DNA potentiates the risk of insertional mutagenesis and
oncogene activation (Thomas et al., 2003). This risk materialized
Fig. 1. Acetylation of the MuLV IN protein. Acetylation of MuLV IN with p300 catalytic
domain was performed as described in Materials and methods. Protein samples were
subjected to SDS-PAGE and stained with Coomassie blue (left) or subjected to
autoradiography (right). Lanes 1, MuLV IN 1–407; Lanes 2, MuLV IN 1–397; Lanes 3,
BSA; Lanes 4, histone control. Positions of migration of prestained molecular weight
broad range markers (BioRad) are indicated.
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a direct result of integration near the LMO2 proto-oncogene (Hacein-
Bey-Abina et al., 2003). Indeed, the use of integration-deﬁcient vectors
is a promising alternative, however, difﬁculty in obtaining adequate
levels of sustained gene expression has been described in recent litera-
ture (Bayer et al., 2008; Yu et al., 2008).
Treating cells with histone deacetylase (HDAC) inhibitors has
been reported to modulate the expression from the integrated provi-
rus (Katz et al., 2007) as well as unintegrated HIV-1 genomes (Kantor
et al., 2009). Acetylation of histone proteins is a well-known epige-
netic marker for active transcription (Carrozza et al., 2003;
Jenuwein and Allis, 2001) and response of viral promoters to the
HDAC inhibitor trichostatin A (TSA) is promoter-dependent
(Vanniasinkam et al., 2006). For MuLV, the chromatin state of the
unintegrated LTR DNA is not deﬁned, and MM-PCR suggests that the
termini are protected within an extended footprint (Chen et al.,
1999; Wei et al., 1998). The need to establish a transcriptionally
active state in the LTR of the provirus in the normal life cycle has
also been suggested (Bruce et al., 2008). It has previously been
reported that the CTD of HIV IN is acetylated on four lysine residues
by the histone acetyltransferases (HATs) GCN5 and p300 and is
recognized by the host KAP1 protein (Allouch et al., 2011; Cereseto
et al., 2005; Terreni et al., 2010; Topper et al., 2007), although the
requirement for acetylation of HIV-1 IN has been debated (Topper
et al., 2007). Additional DNA modeling of the HIV-1 IN CTD based
on the structure of prototype foamy virus (PFV) CTDs, predicts that
the lysine residues involved in acetylation are located on the interior
of the intasome-DNA complex.
In an effort to further understand the effect HDAC inhibitors might
have on expression from unintegrated DNA, we have analyzed several
IN mutants of MuLV. We ﬁnd that expression from the unintegrated
viral promoter is enhanced by the presence of HDAC inhibitors in a
temporally regulated fashion. Although MuLV IN can be acetylated in
vitro by the HAT domain of p300, the enhancement is independent of
MuLV IN K376. IN K376 is the only lysine present in the region
analogous to HIV-1 IN where acetylation has been observed.
Technologically, the ability to increase expression from unintegrated
DNA would present a signiﬁcant advantage when considering the use
of non-integrating vectors for gene therapy applications.
Results
Acetylation of MuLV IN
It has previously been reported that four lysine residues (K258,
K264, K266, and K273) within the CTD of HIV-1 IN are a substrate
for acetylation by host factors, and this acetylation has pleiotropic
effects on viral replication (Allouch et al., 2011; Cereseto et al.,
2005; Terreni et al., 2010). Here, the potential of the MuLV IN protein
to serve as a substrate of the p300 catalytic domain was examined in
vitro in the presence of 14C-labeled acetyl-CoA. Two bacterially
expressed and puriﬁed MuLV IN constructs, IN 1–407 and 1–397
were tested and the modiﬁed proteins were then analyzed by SDS-
PAGE and autoradiography. Shown in Fig. 1 (right lanes 1 and 2),
both the full-length IN 1–407 and the C-terminal truncation, IN
1–397 corresponding to the predicted ~45 kDa proteins were labeled
by 14C-acetyl-CoA. The acetylation of histones served as a positive
control for the reaction (Fig. 1, right, lane 4); as a negative control,
no acetylation of BSA was detected (Fig. 1, lanes 3). Interestingly,
several minor protein break-down products visible by Coomassie
staining (Fig. 1, left) were enriched for labeling with the 14C-acetylation
reaction (Fig. 1, right). Of interest is the ~20 kDa fragments whose
migration varied with the predicted truncation of the C-terminus
suggesting that this fragment corresponds to the C-terminal third of
the IN protein. These results indicate that at least one acetylation site
maps within the MuLV IN CTD.Characterization of MuLV IN mutants
Sequence homology is low across the CTDs of various retroviral
INs, however, structure-based sequence alignments between proto-
type foamy virus (PFV) (Hare et al., 2010b), HIV-1 (Chen, 2000;
Hare et al., 2010b; Krishnan et al., 2010) and MuLV INs (P. Rossi per-
sonal communication) reveal that K370 in PFV and K266 in HIV-1 are
homologous to K376 in MuLV IN (Fig. 2A).
To determine whether K376 of MuLV IN affects viral replication, the
residue was mutated to either alanine (K376A) or arginine (K376R). In
addition, it has been suggested that the extreme C-terminus of HIV-1
IN can inﬂuence the phenotype of the lysine mutants (Topper et al.,
2007). To further probe the role of the C-terminus of IN, we
constructed several truncated IN proteins with and without the
K376R/A mutations. The truncated IN, (ΔC), lacks 23 amino acids
from the extreme C-terminus and has previously been shown to be
viable in vivo (Roth, 1991). Similarly, for HIV-1 IN it has been shown
that truncation of the extreme C-terminus allows for viral replication,
however, the sequential deletion of amino acids negatively impacts
IN activity (Dar et al., 2009; Mohammed et al., 2011). A catalytic site
mutant (D184N) was also included as a control for IN defective in inte-
gration (Steinrigl et al., 2007). Fig. 2B outlines the mutations within the
CCD and CTD of MuLV IN utilized in these studies.
The HDAC inhibitor TSA affects viral propagation
To determine what effect the HDAC inhibitor TSA would have on
viral replication, wild-type (WT) ecotropic MuLV provirus, pNCA-C,
along with the various mutant proviral constructs described above,
were transiently transfected via DEAE-dextran into canine D17pJET
cells (Goff et al., 1981). D17pJET cells stably express the ecotropic
MuLV receptor (MCAT) and therefore allow for the spread of replica-
tion competent virus. To monitor viral ﬁtness, the spread of WT and
mutant virus was monitored over time by the presence of reverse tran-
scriptase (RT) activity released into the supernatants. Fig. 3 reveals that
supernatant from cells transfected with the WT proviral DNA become
RT positive at day 6. The presence of TSA during a WT MuLV infection
did not increase the time course of viral passage, with initial detection
of reverse transcriptase activity remaining at day 6. In contrast, the ad-
dition of TSA increases the replication kinetics of virus bearing the
truncated (ΔC) IN by three days and accelerates the replication rate
of the K376R mutant by a full week. DNA sequence analysis indicated
the IN mutations were maintained in the TSA treated sample, ruling
Fig. 2. IN constructs and sequence alignments. (A) Sequence alignment of MuLV, PFV, and HIV-1 CTDs. Secondary structural elements are shown above where E denotes residues in
a beta conformation and H denotes residues in a helical conformation (β, beta strands; η, 310 helix). Asterisk denotes K376 in MuLV and the homologous lysine residues in PFV and
HIV-1 reported. Amino acid numbering corresponds to MuLV IN. The MuLV CTD was structurally aligned (P. Rossi, personal communication) to PFV and HIV-1 CTDs with UCSF
Chimera (Pettersen et al., 2004). (B) Diagram depicts the three domains of IN: Zn+ binding NTD, CCD, and CTD with residues of interest highlighted. Gray line in the NTD denotes
the additional 50 amino acids in MLV IN not present in HIV IN. Gray line in CTD marks the non-essential extreme C-terminal 23 amino acids.
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constructs, including K376RΔC, K376A, or D184N, became RT positive
(data not shown). These results suggest that acetylation of IN K376 is
not responsible for the enhanced viral kinetics, however, we cannot
rule out the possibility that the HDAC inhibitors are acting on other
Lys residues within IN. Alternatively, these results could be explained
by the effects of HDAC inhibitors on cellular proteins.
Mutation of IN K376 decreases integration
Many IN mutations can have pleiotropic effects (Engelman et al.,
1995), including blocks at various stages of reverse transcription. To
further investigate the defects in viral spread and uncover the
mechanism by which TSA affects viral kinetics, we analyzed the levels
of viral replicative intermediates as well as integrated provirus with
qPCR. For qPCR analysis, VSV-G pseudotyped viral particles were
used to infect TE671 cells in a single round-of-infection. To monitor
replication intermediates we quantiﬁed minus strand strong stop
products (MSSS), plus strand extension products (PSE), and 2-LTR
circle junctions, a dead-end product known to increase in quantity
in the presence of defective IN proteins (Colicelli and Goff, 1985,
1988; Donehower and Varmus, 1984; Roth et al., 1990). Integrated
proviral DNA was quantiﬁed by Alu-PCR.
Virus producing cell lines were established in canine D17 cells
containing the mutant viruses (NeoR) and packaging the reporter
gene gfp (GIP). To conﬁrm proper assembly of virus particles and
verify that similar levels of mutant IN proteins were present, western
blot analysis was performed on supernatant fractions from virus pro-
ducing cells. Uniform levels of three viral proteins (RT, IN, and CA)
were present among the viral constructs and sequence analysis ofFig. 3. RT assay. Reverse transcriptase assay of viral supernatants from DEAE-dextran
transfected cells at the indicated times post transfection with (+) and without (−)
TSA. Results are representative of a minimum of three independent experiments.genomic DNA extracted from virus producing cells conﬁrmed the
presence of the predicted IN mutations (data not shown).
Fig. 4A compares the relative levels of MSSS, PSE replication inter-
mediates and 2-LTR circle junctions of virus bearing the IN K376R and
IN K376A mutations to that of WT virus at 24 h post infection. Viral
infections were normalized to the level of vRNA within particles, as
determined by qPCR using the MSSS primers. Viral intermediates for
MSSS and PSE were not statistically different from the WT infection
indicating that a block in replication does not explain the delay inFig. 4. qPCR of replication products and Alu-PCR. (A) qPCR of replication products.
Graph plots the fold-increase in the amount of PCR products relative to WT virus at
24 h post infection for minus strand strong stop (MSSS), plus strand extension (PSE)
and 2-LTR circle products. (B) Alu-PCR. Graph plots the fold decrease in integrated
provirus for IN mutants relative to WT IN at 18 days post infection. Results are mean
with standard error, N=3. Statistical signiﬁcance was determined by one-way
ANOVA (***, Pb0.001; **, Pb0.01; *, Pb0.05; n.s., not signiﬁcant).
Fig. 5. Effects of integrase reverse transcrtipase and HDAC inhibitors on transgene
expression. (A) WT viral infection in the presence or absence of the IN inhibitor raltegravir
and TSA 3 dpi. (B) WT viral infection in the presence and absence of the RT inhibitor AZT
3 dpi. GFP was measured by ﬂow cytometry in cells infected with WT virus. Cell number
is represented along the y-axis, and GFP intensity is measured on the x-axis.
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in 2-LTR circular products accumulated for virus bearing the IN K376R
and K376Amutants, ~7-fold and ~13-fold respectively. This data indi-
cates that mutations in IN at K376 affect viral integration and corre-
lates with the observed defects in virus propagation (Fig. 3).
To further conﬁrm a defect in integration, Alu-PCR was performed
to quantify integrated provirus. To eliminate the potential contribu-
tion of unintegrated viral DNA from the analysis, genomic DNA was
obtained 18 days post infection. Fig. 4B displays the fold decrease in
integration, relative to WT infection, for the IN mutants described in
Fig. 2B. For the two IN mutants (IN ΔC and IN K376R), which were
viable but displayed a delayed replication phenotype, we observed a
2-fold decrease in integration (IN ΔC) and a roughly 5-fold decrease
in integration (IN K376R). Analysis of the integrants generated in
TE671 cells by IN K376R indicated the global target site preference
with respect to transcriptional start sites and CpG island did not differ
signiﬁcantly from that published in WT MuLV (Wu et al., 2003),
eliminating chromosomal positional effects as the cause for decreased
gene expression (data not shown).
A more dramatic decrease in viral integration was observed with IN
mutants incapable of achieving a sustainable level of infection. The
K376RΔC IN mutation imparted a roughly 50-fold decrease in integra-
tion, whereas the K376A CTD mutation and the catalytic mutant,
D184N, showed a 150–200 fold decrease in the number of integrants.
These results suggest that the ability of a virus to spread is dependent
upon an integrated provirus. The effect of TSA on the kinetics of viral
spread could be acting on either the integrated or unintegrated proviral
DNA. To address this, we set out to deﬁne the expression of MuLV from
unintegrated DNA and further characterize the mechanism by which
TSA enhances viral spread.
HDAC inhibitors increase expression from unintegrated DNA
Gene expression from integration-defective retroviral vectors is sig-
niﬁcantly lower than the level of expression from integrated provirus
(Bayer et al., 2008; Nightingale et al., 2006; Philippe et al., 2006;
Rahim et al., 2009; Sloan and Wainberg, 2011; Yu et al., 2008). We
hypothesized that gene expression can be driven from distinct DNA
populations in infected cells: a low-level of gene expression driven
from unintegrated DNA and a high level of gene expression, character-
istic of retroviral vectors, driven from integrated provirus. To deﬁne
these populations and determine if the unintegrated population is re-
sponsive to treatment with TSA, viral replication was performed
using a single round-of-infection experiment in TE671 cells with WT
IN virus packaging the gfp reporter gene. Infected cells were harvested
at 72 h post infection and analyzed by ﬂow cytometry. The GFP expres-
sion proﬁle of WT virus was examined in the presence and absence of
the integrase inhibitor raltegravir (Fig. 5A). To compare the various
panels of GFP expression in Fig. 5, we deﬁne four categories of cells
based on the mean ﬂuorescence intensity (MFI) of GFP: cells with no
GFP expression (GFPnegative; MFI b100); cells expressing low levels of
GFP (GFPlow 100≤MFI ≤101); cells expressing medium levels of GFP
(GFPmedium 101≤MFI ≤102); and cells expressing high levels of GFP
(GFPhigh; MFI >102). Virus bearing WT IN resulted in a uniform popu-
lation that expressed GFPhigh (Fig. 5, top). Raltegravir treatment results
in a near complete loss of the GFPhigh population and the correspond-
ing appearance of GFPlow and GFPmedium cells. In the presence of TSA,
these cells show a positive shift in theMFI of GFP. Since the mechanism
of action of raltegravir is to block the strand-transfer reaction, these re-
sults indicate that a population of unintegrated DNA exists that can
allow low-levels of gene expression that is responsive to TSA.
To conﬁrm that the GFP measured in the infected cells resulted
from gene expression and not protein transfer of GFP in the viral par-
ticles, we treated target cells with the RT inhibitor AZT (Voelkel et al.,
2010). In the presence of AZT we were unable to measure any GFP in
the infected cells (Fig. 5B). This indicates that reverse transcription isrequired to generate the template for pol II dependent transcription
and the GFP detected in infected cells is not a result of packaging
GFP protein into the viral particles. These results from experiments
with raltegravir and AZT are consistent with the conclusion that the
GFP in the TSA-responsive GFPlow and GFPmedium cells originates
from unintegrated viral DNA.
Using the single round-of-infection system, the effects of TSA-
treatment on integrase-defective mutants was examined by monitoring
GFP expression. Fig. 6 compares WT with the integration defective
D184N and K376A mutants along with IN K376R virus. Histogram plots
in Fig. 6A display the MFI of GFP at 3 days post infection (dpi) and
10 dpi and are quantiﬁed in Fig. 6B. At 3 dpi, cells infected with WT
virus fall exclusively into the GFPhigh population, whereas cells infected
with IN K376R are present in two distinct populations (GFPlow/medium
and GFPhigh). Cells infected with integration defective virus fall
exclusively into the GFPlow and GFPmedium population. At 3 dpi when
TSA is present in the culture medium, cells in the GFPlow and GFPmedium
population show a shift in theMFI of GFP. These results are highlighted in
Fig. 6B by the increased percentage of cells in the GFPmedium category,
having shifted from the GFPlow category when TSA is present. While
the proﬁle of WT virus remains largely unchanged, cells infected with
IN K376R show an increase of ~15% in the GFPmedium category. Cells
infected with the IN-defective mutants K376A and D184N show an
even greater effect with the amount of GFPmedium cells increasing ~30–
35%. The analysis of cells at 10 dpi, a time when the majority of
unintegrated viral DNA is no longer present (Butler et al., 2002) provides
additional evidence supporting the hypothesis that cells populating the
GFPlow and GFPmedium categories harbor unintegrated DNA. As would
be expected for GFP expressed from integrated provirus, the GFP positive
cells that persist until day 10 fall into the GFPhigh category. This category
appears only when cells are infected with integration-competent virus.
Additional HDAC inhibitors were also tested and yielded similar results
(data not shown). The additional HDAC inhibitors included 4-
phenylbutryate (PBA), valproic acid (VPA), and sodium butyrate. These
results suggest that a general effect on HDACs is responsible for the
observed phenotype.
To further deﬁne the temporal effect of TSA on unintegrated DNA,
single round-of-infection studies were performed with IN K376R
virus packaging the gfp reporter gene. In the virus replication assay
shown in Fig. 3, the HDAC inhibitor TSA was present throughout the
Fig. 6. GFP expression from unintegrated DNA. (A) GFP expression was measured by ﬂow cytometry in infected cells at 3 days post infection 3 (dpi) and 10 days post infection
(10 dpi). The effects of adding TSA to the cell culture medium during infection were also monitored. Cell number is represented along the y-axis and GFP intensity is measured
on the x-axis. (B) Quantitation of the results from panel A. Neg; MFI b100; Low: 100≤MFI ≤101; Med: 101≤MFI ≤102; and High; MFI >102.
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time-dependent manner, target cells were treated with TSA either
12 h prior to infection, during the infection, or 48 h post infection.
Infected cell cultures were harvested at 72 h post infection and
analyzed by ﬂow cytometry (Fig. 7). In this experiment, IN K376R
the GFPlow and GFPmedium population of cells predominate with a
smaller population comprised of GFPhigh cells. The GFPlow and
GFPmedium cells corresponding with the proposed unintegrated DNA
pool are responsive to TSA, showing a positive shift in MFI. Cells
treated with TSA 12 h prior to infection display similar expression
proﬁles to those treated at the time of infection. In contrast, TSA
had no discernible effect on GFP expression in cells treated 48 h
post infection. Time course analyses have indicated viral integration
occurs within the ﬁrst 12–24 h after infection (Roe et al., 1997).
These studies support the results that the HDAC inhibitors are not
acting through the integrated provirus, but rather, are required at
the time when the unintegrated provirus is established in the newly
infected cells.Discussion
Post-translational modiﬁcation of proteins is a well-established cel-
lular mechanism to modulate function in response to various spatial,
temporal, and environmental cues. Acetylation of lysine residues
within proteins is one such modiﬁcation, most notably recognized as
an epigenetic modiﬁer of histone proteins. The presence of acetylated
histones is generally associated with active transcription (Carrozza et
al., 2003). Previous studies aimed at understanding transcriptional
repression of integrated provirus has shown that HDAC inhibitors are
capable of re-activating expression from a subpopulation of integrants,
presumably through modiﬁcation of the histone proteins (Katz et al.,
2007). In a WT MuLV infection, transcription is driven from the inte-
grated proviral DNA and sustained viral infection is not observed in
the absence of IN protein. A recent interest in utilizing non-
integrating retroviral vectors for gene expression, however, has raised
the question as to whether protein acetylation plays a role in transient
expression from unintegrated viral DNA.
Fig. 7. Temporal requirement for TSA effect on transgene expression. Comparison of cells
infected with WT and IN K376R mutant virus and treated with the HDAC inhibitor TSA at
various time points. Untreated, no TSA added; Pre-treatment, TSA added 12 h prior to
infection; Time of, TSA added with viral infection; Post-treatment, TSA added 48 h post
infection. GFP was measured by ﬂow cytometry at 3 dpi. Cell number is represented
along the y-axis, and GFP intensity is measured on the x-axis.
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pression, it has been demonstrated that the HIV IN CTD itself is tar-
geted for acetylation (Cereseto et al., 2005; Terreni et al., 2010),
although this acetylation appears to be dispensable for viral replica-
tion (Topper et al., 2007). Data presented in this study indicates
that the MuLV IN is also a substrate for in vitro acetylation by the
p300 protein. To test whether mutation of the CTD from MuLV IN
would have an effect on transgene expression, GFP expression was
monitored in infected cells. When tested, there was in fact a clear de-
crease in gene expression following viral infection with IN K376 mu-
tant viruses. This effect, however, was modulated by HDAC inhibitors
and therefore, our results indicate that acetylation of K376 in MuLV IN
is not responsible for this phenotype. We cannot eliminate the possi-
bility that acetylation of alternative lysines beyond K376 of MuLV IN
could be regulated.
Utilizing the IN inhibitor raltegravir, aswell as a catalytically inactive
IN mutant (D184N), we determined that the HDAC inhibitors were
acting on unintegrated viral DNA. From this, we infer that upon addition
of HDAC inhibitors, changes in chromatin structure of the unintegrated
DNA alter the accessibility of viral DNA to host transcription factors.
Currently there is no direct evidence that DNA within the MuLV PICs
is chromatinized. Alternatively, the effects of HDAC inhibitors could
affect cellular proteins required for the infectious process. Various cellu-
lar proteins are targeted for acetylation and it has previously been
shown that HDAC inhibitors can affect intracellular trafﬁcking (Barua
and Rege, 2010).
These studies are directly relevant to the ﬁeld of non-integrating
viral vectors (Banasik and McCray, 2010). Arguably, one of the great-
est beneﬁts to using a retroviral-based vector is the high-level of gene
expression associated with an integrated virus. However, the short-
falls are also established, notably the eventual transcriptional repres-
sion that occurs over time and integration of the DNA itself can lead to
gene disruption and/or oncogene activation. Various studies have re-
cently explored the potential use of non-integrating retroviral vec-
tors, where the IN protein contains point mutations that render it
inactive. For non-integrating retroviral vectors, a bottleneck thatremains is the low level of expression obtained from these vectors
in comparison with the integrated provirus. The results from these
studies identify a means to transiently improve the level of expres-
sion, using a combination of speciﬁc MuLV IN mutations and HDAC
inhibitors. Notably, transgene expression was detected from the
majority of the infected cells, indicating expression from an abundant
proviral DNA species. The addition of TSA at two days post-infection,
a time when circular products are abundant, has no effect on GFPlow
and GFPmedium expression. We interpret this time dependence of
TSA addition to suggest that it is required early during viral replica-
tion to prevent the formation of a repressed state within the viral
LTR. In the current study, the effect was only measured on expression
from the viral LTR promoter.Whether the observed activation/repression
would extend to internal promoters within self-inactivating (SIN) vec-
tors is of interest and is currently being examined.
Conclusion
Productive retroviral infection is driven by expression from the in-
tegrated virus. In these studies, we demonstrate increased transgene
expression from the unintegrated proviral DNA in the presence of
HDAC inhibitors. Furthermore, treating cells harboring unintegrated
viral DNA with HDAC inhibitors is capable of altering the kinetics of
viral replication, however, it is not sufﬁcient to achieve a sustained in-
fection of a non-integrating vector through multiple rounds of infec-
tion in a dividing cell. Utilization of the described IN mutants in
combination with HDAC inhibitors can increase the expression of
transgenes from non-integrating vectors and has direct applications
for retroviral vectors in molecular biology or gene therapy applica-
tions, for example in iPS formation, where transient expression of
reprogramming factors is required.
Materials and methods
Generation of plasmids
Construction and analysis of pNCA-C, a viable, replication-
competent M-MuLV proviral construct has been previously described
(Felkner and Roth, 1992). The pNCA-C-XN-SU8M-MuLV proviral con-
struct (ΔC) was derived from pNCA-C (Roth, 1991; Seamon et al.,
2000). This contains a Not I linker within the Xba I site at the 3′ termi-
nus of the M-MuLV pol gene, yielding a 23-amino-acid C-terminal
truncation of the MuLV IN protein plus a suppressor tRNA in the 3′
long terminal repeat (LTR) (SU8) (Lobel and Goff, 1984).
To generate pNCA-C-Neo and pNCA-C-XN-Neo (ΔC), vectors
pNCA-C and pNCA-C-XN-SU8were used as templates. The A nucleotide
in the ATG start codon of Env was mutated to a C, via overlapping PCR,
maintaining the coding sequence in IN. The coding region of the neo
gene obtained from the vector pRVL (Bupp and Roth, 2002) was then
cloned in such that the start codon overlapped with the stop codon
of the IN gene. Speciﬁcally, the last base in IN along with the stop
codon, CTAA, was mutated to ATGA, rendering the IN protein product
unaltered. The neo gene is therefore expressed as a spliced message
in place of env. Nucleotide residues ATAAAATAAA, identical to that
immediately following the Env stop codon, along with a NsiI restriction
site were added adjacent to the neomycin stop codon via PCR. The
resulting overlapping PCR product was then digested with HindIII
and NsiI and cloned into the pNCA-C vector. PCR reactions were carried
out with KOD polymerase (Novagen).
The pNCA-C K376R/A and D184N mutations were generated by
overlapping PCR with pNCA-C, pNCA-C-XN-SU8, pNCA-C-Neo, and/
or pNCA-C-XN-Neo serving as the template. The PCR reactions were
carried out with KOD polymerase (Novagen) and full-length insert
products were gel isolated. The K376 mutant PCR products were
digested, and cloned into pNCA-C, pNCA-C-XN-SU8, pNCA-C Neo,
and pNCA-C-XN-Neo accordingly at the HindIII and NsiI sites. The
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cloned into pNCA-C and pNCA-C-Neo.
IN puriﬁcation
pGV358 (gift from Kushol Gupta, Univ. of Pennsylvania) is a pET-
Duet based vector that has an Mxe intein in frame at the C terminus
followed by the non-cleavable hexahistidine tagged chitin binding
domain. M-MuLV integrase from positions 1–407 and 1–397 were
PCR ampliﬁed from the pNCA-C (Felkner and Roth, 1992) template
in which a single point mutation was introduced to abolish the
NdeI site in the integrase coding region. The PCR fragment was
cloned between the NdeI and XhoI sites of pGV358. The following
primers were used: 1–407 IN and 1–397 IN forward primer (NdeI
site underlined) – 5′ GGAATTCCATATGATAGAAAATTCATCACCCTA
CACCTCAG 3′. 1–407 IN reverse primer (XhoI site underlined) – 5′
CCGGCTCGAGGGCCTCGCGGGTTAACC 3′. 1–397 IN reverse primer
(XhoI site underlined) – 5′ CCGGCTCGAGGTTTTGAGAGCGTT
GAACGCGCC 3′. Plasmids were introduced into BL21(DE3) E. coli
and protein expression was induced for a 1 liter culture at an
O.D.600 of 0.7 for 24 h at 17 °C. Cells were harvested and lysed in ice
cold buffer containing 50 mM sodium phosphate pH 8.0, 300 mM
NaCl, 10 mM CHAPS, complete EDTA protease inhibitor tablets
(Roche). Fusion proteins were puriﬁed using Ni NTA (Qiagen) and
chitin beads (New England Biolabs) as per the manufacturer's
recommendations. IN 1–407 and IN 1–397 were released from the
fusion protein by incubating for 48 h at 4 °C with 20 mM HEPES pH
8.0, 1 M NaCl, 10% glycerol, 0.1 mM EDTA, 50 mM DTT (Fluka),
0.01% Igepal CA −630 (Sigma) and 10 μM zinc sulfate. Cleaved
protein was then further puriﬁed using SP-Sepharose chromatogra-
phy (GE Healthcare). The puriﬁed fraction obtained against a salt
gradient of 250 mM–2 M NaCl was then concentrated using Ultracel
30 K concentrator (Millipore) in the presence of 0.01% Igepal CA–630
to ~0.5–1 mg/ml and used for the acetylation assays. The ﬁnal buffer
composition of the protein is 20 mM HEPES pH 7.0, 250–750 mM
NaCl, 10% glycerol, 1 mM DTT, 0.1 mM EDTA, 0.01% Igepal CA–630,
10 μM ZnSO4.
HAT assay
4 μg recombinant truncated IN (1–397) or full length IN (1–407)
protein was incubated for 30 min at 30 °C with 3.8 μg p300 (BML-
SE451, Enzo Life Sciences) in 25 μl Tris–HCl (50 mM, pH 8.0) containing
10% glycerol, 0.1 mM EDTA, 0.08 uCi of [14C] acetyl-CoA (5 mCi/mmole,
MP/ICN), and 0.16 μg Acetyl-CoA (20-192A, Millipore). 4 μg Core His-
tone (13-107B, Millipore) and BSA (Sigma) were used as positive and
negative controls. After protein acetylation, reaction mixtures were
heated at 95 °C for 5 min with 1X LDS sample buffer (Invitrogen) and
subjected to electrophoresis on a SDS 4–20% gradient polyacrylamide
gel (Pierce). The gel was dried on a gel dryer (Model 583, BioRad)
and exposed to Kodak XAR ﬁlm.
Cell culture
The generation and maintenance of canine D17pJET cells stably
expressing the ecotropic M-MuLV receptor (MCAT) (Albritton et al.,
1989) has been previously described (O'Reilly and Roth, 2000). Provi-
ral DNA was transiently introduced into D17pJET cells to monitor the
time course of virus replication and to generate cell lines producing
modiﬁed IN containing virus. D17pJET cells were split at 1×105
cells per 60 mm dish and cultured in DMEM (Gibco) with 10%
serum. The following day proviral DNA was transiently introduced
in duplicate with DEAE-dextran using 250 ng of DNA (McCutchan
and Pagano, 1968). The cells were then incubated at 37 °C in 5 ml of
fresh medium and maintained with and without 6.25 nM trichostatin
A (HDAC inhibitor). Upon conﬂuence, supernatant was collected andcells were passed to 10 cm plates. Supernatant was collected at
conﬂuence over the course of several weeks and assayed for RT
activity (Goff et al., 1981). Virus producing cell lines were maintained
in culture for replication kinetics experiments.
To generate virus producing D17 canine cell lines, 293T CeB cells
(Cosset et al., 1995) were transfected with 3 μg of WT or IN mutant
pNCA-C-Neo plasmids in combination with 3 μg of pHIT-G plasmid
DNA (VSV-G) using the Mammalian Transfection Kit [stable CaPO4]
(Stratagene) as described by the manufacturer. The following
morning the medium was replaced with 5 ml of fresh medium
supplemented with 10 mM Na-butyrate for 6 h to enhance expression
from plasmid DNA (Soneoka et al., 1995). The medium was again
changed and virus was collected after approximately 36 h. Viral
supernatant was used to infect D17 cells for 72 h thereafter cells
were treated with G418 (400 μg/ml). Upon selection of G418 resistant
producer cell lines, the proviral reporter construct, pGIP (Chen et al.,
2001), was then introduced into these D17-Neo cell lines in a similar
fashion as described above. D17-Neo virus producing cell lines were
selected with 2.5 μg/ml of puromycin yielding the D17-Neo-GIP cell
lines for subsequent viral infection assays.
Infections
Single round of infection experiments into human TE671 cells for
FACS analysis and Alu-PCR was performed by transfecting D17-Neo-GIP
producer cell lines with 3 μg of pHIT-G plasmid DNA (VSV-G). Approxi-
mately 2×105 cells were plated on 10 cm dishes the evening prior to
transfection. The VSV-G pseudotyped virus was collected in 10ml and
equivalent virus productionwas conﬁrmed by anti-CAwestern blot anal-
ysis using a 1/1000 dilution of goat anti-MuLV CA (75S-287) from the
NCI-BCB Repository (distributed by Microbiological Associates, Inc.).
Similarly, to detect RT and IN from viral particles, 10 ml of viral superna-
tant was collected from conﬂuent producer cell lines and centrifuged and
prepared as above, then run on a 10% SDS-PAG. A 1/1000 dilution of a
rabbit polyclonal antibody recognizing both RT and INwas used to detect
protein from the mutant IN virus producing cell lines (Tanese et al.,
1986). Approximately 1×105 TE671 cells were plated per 60 mm dish
the evening prior to infection. The following day virus was added to
cells at 37 °C for 72 h. Where appropriate, HDAC inhibitors were added
to the TE671 target cells either the evening prior to infection (pre-
treatment), at the time of infection, or 48 h after the virus was added
(post-treatment). HDAC concentrations used during infection were as
follows: trichostatin A (TSA), 20 nM; sodium 4-phenylbutryate (PBA),
5 mM; valproic acid (VPA), 2 mM; sodium butyrate, 2 mM. Where
appropriate, the IN inhibitor raltegravir was added to a ﬁnal concentra-
tion of 100 nM at the time of infection. Raltegravir was obtained
through the NIH AIDS Research and Reference Reagent Program
(www.aidsreagent.org). Where indicated, AZT (Sigma A2169) was
added at 50 μM (Voelkel et al., 2010) to target cells 24 h prior to infec-
tion and remained in the medium for the duration of the experiment.
qPCR
Single round of infection experiments into human TE671 cells
were performed by transfecting D17-Neo-GIP WT IN, IN-K376R IN-
K376A, and IN D184N producer cell lines with 2 μg of pHIT-G plasmid
DNA (VSVG) using the Fugene 6 (Roche) as described by the manu-
facturer. Approximately 5×105 cells were plated on 10 cm dishes
the evening prior to transfection. The VSV-G pseudotyped virus was
collected at 48 h post transfection and stored at−80°C. Viral particles
were quantiﬁed and normalized by qPCR using primers/probe set for
quantiﬁcation of minus strand strong stop (MSSS) intermediates (see
below). pNCA-C-Neo plasmid was used to establish the standard
curve. Viral RNA was puriﬁed with the QIAamp Viral RNA mini kit
(Qiagen) and cDNA synthesis was performed with using Superscript
III Reverse Transcriptase primed with Random Hexamers (Invitrogen).
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dishes at approximately 2×105 cells per dish. The following day, cells
were infected in triplicate with 2 mL viral supernatants (6.7×109
copies/mL) per dish in the presence of 8 μg/mL polybrene (Sigma,
H9268) at 37 °C. Infected cells were harvested at 24 h post-
infection, and genomic DNA was puriﬁed with the DNeasy Blood &
Tissue Kit (Qiagen) and applied for qPCR.
qPCR reactions were prepared using the TaqMan Universal PCR
Master Mix, No AmpErase UNG (Applied Biosystems) and analyzed on
a 7900HT Fast Real-Time PCR System (Applied Biosystems). Each
reaction was performed in triplicate in a total volume of 25 μl using
300 ng of genomic DNA as template. The reaction conditions were as
follows: 1 cycle at 50 °C for 2 min, 1 cycle at 95 °C for 10 min, followed
by 95 °C for 15 s and 60 °C for 1 min for 40 cycles. Primers were used
at a concentration of 900 nM and probes were used at 250 nM. The
primers and probe used for quantiﬁcation were as follows: Primer A,
(5′- GCCAGTCCTCCGATTGACTG -3′); Primer B, (5′- TGACGGGTAGT-
CAATCACTCAGAG -3′); Primer C, (5′- AATCGGACAGACACAGA-
TAAGTTGC -3′); Probe E, (5′- /56-FAM/CATCCGACTTGTGGTCTCGCTG
TTCC/36-TAMSp/ -3′). Primers for quantiﬁcation of minus strand strong
stop (MSSS) intermediateswere Primer A and Primer B. Primers A and C
were used for quantiﬁcation of plus strand extension (PSE). The probe
used for MSSS and PSE was Probe E. Primers used for quantiﬁcation
of 2-LTR circles were 2-LTR forward: 5′-CTT GTG GTC TCG CTG TTC
CTT-3′ and 2-LTR Reverse: 5′-TGC AAA ATG GCG TTA CTT AAG C-3′
and 2-LTR probe: 5′-/56-FAM/ TGA AAG ACC CCA CCT GTA GGT TTG
GCA AG/36-TAMSp/-3′. Reactions were normalized to GAPDH using
primers: 5′- TCGACAGTCAGCCGCATCT -3′ and 5′- CTAGCCTCCCGGG
TTTCTCT -3′ and probe: 5′- /56-FAM/ TCGCCAGGTGAAGACGGGCG/
3IABIk_FQ/ -3′.
For Alu-PCR reactions in human TE671 cells to quantify integrated
provirus, single round of infection experiments were performed using
VSV-G pseudotyped virus as described above. Genomic DNA was har-
vested from cells 18 days post infection (Bruce et al., 2008) and 4 ul
(~400 ng) of genomic DNAwas used as template for an initial ampliﬁca-
tion under the following reaction conditions: 1 cycle at 95 °C for 5 min,
followed by 12 cycles at 95 °C for 15 s, 66.8 °C for 30 s, and 68 °C for
1 min 30 s. Primers were used at a concentration of 300 nM each. LTR
forward bp282 primer (5′- CAGCCCTCAGCAGTTTCTAGAGA -3′). Alu
primer (5′-AGCTACTCGGGAGGCTGAGG -3′). PCR reactionswere carried
out with KOD polymerase (Novagen) and the resulting PCR productwas
used for a subsequent nested qPCR reaction. qPCR reactions to quanti-
tate proviral DNA followed the qPCR conditions outlined above with
the following primers/probes: LTR taqman forward primer: (5′-
TCAGTTCGCTTCTCGCTTCTGT -3′). LTR taqman reverse primer: (5′- GG
GTTGTGGGCTCTTTTATTGA -3′). LTR taqman probe: (5′-/56-FAM/
CGCGCGCTTCTGCTCCCC/36-TAMSp/ -3). Primers speciﬁc for human β-
actin were used for an internal control to normalize for input DNA. β-
actin forward: (5′- TCACCCACACTGTGCCCATCTACGA -3′). β-actin
reverse: (5′- CAGCGGAACCGCTCATTGCCAATGG -3′). β-actin probe:
(5′- /56-FAM/ATGCCCTCCCCCATGCCATCCTGCGT/TAMSp/ -3′).
Flow cytometry
Infected cells were trypsinized, centrifuged, and resuspended in
1 ml of PBS for analysis of GFP expression by ﬂow cytometry. All
ﬂow cytometry experiments were carried out on a Coulter Cytomics
FC500 Flow Cytometer at the Analytical Cytometry Image Analysis
Core Facility at the Environmental and Occupational Health Sciences
Institute, 170 Frelinghuysen Road, Piscataway, NJ 08854.
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